Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo
Close
Articolul precedent
Articolul urmator
373 0
Căutarea după subiecte
similare conform CZU
615.1-092.4 (1)
General and professional pharmacy (184)
SM ISO690:2012
DRAENERT, Florian Guy, HUETZEN, Dominic, KAMMERER, Peer Wolfgang, PĂLĂRIE, Victor, NACU, Viorel, WAGNER, Wilfried. Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo. In: Structuri arheologice din aşezările epocii fierului în spaţiul tiso-nistrean, 12-15 iulie 2018, Saharna. Cluj -Napoca, România: Editura Mega, 2019, Ediția a IV-a, pp. e369-e374. ISBN 978-606-020-157-1. DOI: https://doi.org/10.1016/j.jcms.2012.01.028
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Structuri arheologice din aşezările epocii fierului în spaţiul tiso-nistrean
Ediția a IV-a, 2019
Colocviul "Structuri arheologice din aşezările epocii fierului în spaţiul tiso-nistrean"
Saharna, Romania, 12-15 iulie 2018

Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo

DOI: https://doi.org/10.1016/j.jcms.2012.01.028
CZU: 615.1-092.4

Pag. e369-e374

Draenert Florian Guy1, Huetzen Dominic1, Kammerer Peer Wolfgang2, Pălărie Victor3, Nacu Viorel3, Wagner Wilfried2
 
1 Philipps-Universität Marburg,
2 Mainz University, Germany,
3 ”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
Disponibil în IBN: 7 ianuarie 2021


Rezumat

Introduction: Bisphosphonates are important and effective drugs in oncology and osteoporosis therapy. They accumulate in the bone matrix becoming released and active by bone resorption. This leads to effective inhibition of tumor cells and bone degradation. A side effect of bisphosphonates similar to other drugs like denosumab is osteonecrosis of the jaws (ONJ). This problem mostly occurs after tooth extraction. We studied the cytoprotectant dexrazoxane known from anthracycline chemotherapy for cytoprotection in nitrogen-containing bisphosphonate treated cells and in the rabbit tibia model to evaluate a possible value in ONJ management. Materials & methods: Human osteoblasts (HOB) P2 cells and Human ginigiva fibroblasts (HGF) P2 cells were treated with zoledronic acid (50 μmol/L) and the cytoprotectant dexrazoxane (600 μmol/L). Analysis included cell viability testing with MTT assay and morphology analysis using CellTracker™ Green CMFDA. A biomaterial carrier (Bio-Oss Collagen) was implanted in the rabbit tibia of 6 female chinchilla bastard rabbits on both sides with drill hole defects (d: 3.2 mm). Implants were loaded with 25 nmol zoledronic acid, with and without 300 nmol dexrazoxane and unloaded in a control group. Analysis included histological examination of undecalcified samples with toloudine blue staining after 10 days. Results: In vitro experiments showed a significantly higher MTT activity in cells treated with zoledronic acid together with dexrazoxane compared to the same cells treated with the bisphosphonate alone in t-test (HOB: p = 0.0003; HGF: p below 0.0001) and one-way ANOVA. Cell morphology changes were consistent with these results. In vivo results showed newly formed bone trabeculae directly growing towards the implanted hydroxylapatite particles and cortical bone interface resorption activities in the control and the experimental group only. Conclusion: The study suggests a possible value of this patented technology for ONJ therapy and prevention with local or systemic application. 

Cuvinte-cheie
Bisphosphonates, Cytoprotectant, Osteonecrosis of the jaws

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-118878</cfResPublId>
<cfResPublDate>2019</cfResPublDate>
<cfVol>Ediția a IV-a</cfVol>
<cfStartPage>e369</cfStartPage>
<cfISBN>978-606-020-157-1</cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/118878</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>Bisphosphonates; Cytoprotectant; Osteonecrosis of the jaws</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction: Bisphosphonates are important and effective drugs in oncology and osteoporosis therapy. They accumulate in the bone matrix becoming released and active by bone resorption. This leads to effective inhibition of tumor cells and bone degradation. A side effect of bisphosphonates similar to other drugs like denosumab is osteonecrosis of the jaws (ONJ). This problem mostly occurs after tooth extraction. We studied the cytoprotectant dexrazoxane known from anthracycline chemotherapy for cytoprotection in nitrogen-containing bisphosphonate treated cells and in the rabbit tibia model to evaluate a possible value in ONJ management. Materials &amp; methods: Human osteoblasts (HOB) P2 cells and Human ginigiva fibroblasts (HGF) P2 cells were treated with zoledronic acid (50 &mu;mol/L) and the cytoprotectant dexrazoxane (600 &mu;mol/L). Analysis included cell viability testing with MTT assay and morphology analysis using CellTracker&trade; Green CMFDA. A biomaterial carrier (Bio-Oss Collagen) was implanted in the rabbit tibia of 6 female chinchilla bastard rabbits on both sides with drill hole defects (d: 3.2 mm). Implants were loaded with 25 nmol zoledronic acid, with and without 300 nmol dexrazoxane and unloaded in a control group. Analysis included histological examination of undecalcified samples with toloudine blue staining after 10 days. Results: In vitro experiments showed a significantly higher MTT activity in cells treated with zoledronic acid together with dexrazoxane compared to the same cells treated with the bisphosphonate alone in t-test (HOB: p = 0.0003; HGF: p below 0.0001) and one-way ANOVA. Cell morphology changes were consistent with these results. In vivo results showed newly formed bone trabeculae directly growing towards the implanted hydroxylapatite particles and cortical bone interface resorption activities in the control and the experimental group only. Conclusion: The study suggests a possible value of this patented technology for ONJ therapy and prevention with local or systemic application.&nbsp;</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-83669</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-84220</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-58927</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-28698</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11432</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-84221</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-83669</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-83669-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Draenert</cfFamilyNames>
<cfFirstNames>Florian Guy</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-84220</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-84220-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Huetzen</cfFamilyNames>
<cfFirstNames>Dominic</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-58927</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-58927-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Kammerer</cfFamilyNames>
<cfFirstNames>Peer Wolfgang</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-28698</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-28698-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Pălărie</cfFamilyNames>
<cfFirstNames>Victor</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11432</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11432-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Nacu</cfFamilyNames>
<cfFirstNames>Viorel</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-84221</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-84221-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Wagner</cfFamilyNames>
<cfFirstNames>Wilfried</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>